Sosei   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (1990)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2005
NCT00141934
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sosei

Active Ingredients

Drugs in Phase 3 Trials (1)

fentanyl (Innovar) (1 trial)

Drugs in Phase 2 Trials (6)

Key: Sosei (2) Acquired (4)

ad 337 (1 trial)

ad 452 (1 trial)

atezolizumab (Tecentriq) (1 trial)

glycopyrronium (robinul) (1 trial)

htl0018318 (4 trials)

htl0039732 (1 trial)

Drugs in Phase 1 Trials (6)

Key: Sosei (0) Acquired (6)

htl0009936 (3 trials)

htl0014242 (2 trials)

htl0016878 (3 trials)

htl0022562 (1 trial)

htl0030310 (1 trial)

pasireotide (signifor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Breakthrough Pain (Phase 3)

Dementia (Phase 2)

Fibromyalgia (Phase 2)

Lewy Body Disease (Phase 2)

Myofascial Pain Syndromes (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 13